Navigation Links
Access Pharmaceuticals Updates MuGard.com With New Product Testimonial
Date:3/6/2012

DALLAS and NEW YORK, March 6, 2012 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care, updated its lead product website, www.MuGard.com, with a new product testimonial video.

To view the testimonial, visit the Testimonials section of the MuGard site or click on the following link: http://www.mugard.com/testimonials/.

Conference Presentation Details:
Tomorrow morning, Mr. Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will present at the Cowen and Company 32nd Annual Health Care Conference, at The Boston Marriott Copley Place in Boston, MA.  Davis is scheduled to present at 8:00am ET.

A live webcast of the audio presentation and company slide deck can be accessed via the following link during the presentation time: http://wsw.com/webcast/cowen6/accp/.

About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.  For more information, please visit www.MuGard.com.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients.  Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company and Media

Contact: Investor RelationsChristine Berni

Donald C. WeinbergerDirector of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208

 


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AccessClosure, Inc. Launches MynxGrip™ Vascular Closure Device
2. Access Pharmaceuticals Receives Final Marketing Approval From SFDA of China for MuGard
3. CAS and Taylor & Francis Collaborate to Improve Scientists Access to Published Research
4. Launch of Access Alliance Opens Lines of Communication Between Labor Unions, Health Care Providers, and Pharmaceutical Companies
5. American Association for Homecare Calls for Market-Based Alternative to Medicares Bidding Program; Cites Lack of Access for Beneficiaries
6. Access Pharmaceuticals MuGard Added to Nationally Ranked Childrens Hospital of Colorado Pharmacy Formulary
7. Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans
8. Revation Systems Launches an Accessible Virtual Care Solution for Healthcare Organizations
9. Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program
10. Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York
11. MedeAnalytics Launches Next-Generation Patient Access Intelligence Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
Breaking Medicine News(10 mins):